Mahana Therapeutics and Bayer in multi-million dollar partnership to commercialize digital therapeutics

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Bayer Mahana Therapeutics digital therapeutics Partnership

Mahana Therapeutics announced last week (August 22) that it was entering into a multi-million dollar distribution and marketing partnership with the consumer health division of Bayer.

The partnership’s aim will be to commercialize digital therapeutics that Mahana specializes in for prescriptions.

“This historic partnership is among the first major investments ever made by a global life sciences company into the emerging marketplace for digital therapeutics. Mahana is proud to collaborate with the Bayer team who share our view that digital therapeutics are a critical part of the future of healthcare,” said Simon Levy, CEO of Mahana.

“Through this agreement, we can further expand the availability of our innovative prescription digital therapeutics for patients and their caregivers around the world who seek effective treatment for chronic conditions.”

Increase informed choices for patients

Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market. The company says it is prioritizing development of products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.

David Evendon-Challis is head of R&D and chief scientific officer for the consumer health division of Bayer.

He added, “Digital therapeutics are a perfect addition to our portfolio of care and tap into new tech-savvy consumers looking for drug-free treatments as well as help eliminate gaps in care provision. We’re excited to partner with Mahana Therapeutics and enter the field of digital therapeutics in consumer health.”

Mahana Therapeutics says its prescription digital therapeutics are designed to empower patients with chronic conditions to live fuller lives. The company’s first product, Mahana IBS, was the first digital therapeutic to receive FDA clearance for the treatment of IBS and provides cognitive behavioral therapy (CBT) to adults with IBS.

Related news

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Related suppliers

Follow us


View more